EMA
- Application: EMEA/H/C/004354
- Marketing authorisation holder: Pharma Mar S.A.
- Local brand name: Aplidin
- Indication: Treatment of multiple myeloma
- Pathway: orphan
- Status: withdrawn
🇪🇺 Aplidin® in European Union
Aplidin® (Aplidin®) regulatory status in European Union.
Marketing authorisation
Other Oncology approved in European Union
Frequently asked questions
Is Aplidin® approved in European Union?
Yes. EMA has authorised it.
Who is the marketing authorisation holder for Aplidin® in European Union?
Pharma Mar S.A. holds the EU marketing authorisation.